01—Abstract
Summary
Summary of the 10-Q filed August 1, 2025. Cited figures are marked; the original filing is the authoritative source.
Boston Scientific Corporation (BSX) reported robust financial results for the second quarter and first six months of 2025, demonstrating significant year-over-year growth in net sales and profitability.
Net sales increased by 22.8% in Q2 2025 to $5.061 billiona, driven by strong operational growth of 21.6% and contributions from recent acquisitions. The company's net income attributable to common stockholders rose substantially to $797 million in Q2 2025, up from $324 million in the prior year period. Key growth drivers included the Electrophysiology business unit, propelled by the adoption of the Farapulse™ Pulsed Field Ablation System, and strong performance across the Cardiovascular and MedSurg segments.
The company also made strategic acquisitions during the period, including Anrei Medical, SoniVie Ltd., Intera Oncology®, and Bolt Medical, Inc., which are expected to enhance its product portfolio and market position. Despite some headwinds such as increased R&D expenses and restructuring charges, BSX maintains a solid financial position and expects continued growth.
02—Key points
Key Highlights
- Net sales for Q2 2025 surged to $5.061 billion, a 22.8% increase year-over-year, driven by strong operational and organic growth, as well as contributions from acquisitions.
- Net income attributable to common stockholders reached $797 million in Q2 2025, a significant increase from $324 million in Q2 2024, reflecting improved profitability.
- The Electrophysiology business unit, particularly the Farapulse™ PFA System, was a major growth driver, demonstrating strong commercial execution and market adoption.
- The company completed several strategic acquisitions in the first half of 2025, including Anrei Medical, SoniVie, Intera Oncology®, and Bolt Medical, aimed at expanding its product offerings and market reach.
- Research and Development (R&D) expenses increased significantly, reflecting ongoing investment in innovation and a robust pipeline of new products.
- Despite a decrease in gross profit margin due to inventory charges and other period expenses, overall profitability improved.
- Boston Scientific reported strong compliance with its financial covenant (leverage ratio of 2.16x vs. 4.75x maximum permitted), indicating a healthy balance sheet and financial flexibility.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q2 FY2025, Boston Scientific Corp kept $0.16.
- Revenue$5.06B100.0%
- Cost of revenue−$1.64B32.3%
- Gross profit$3.42B67.7%
- Operating costs−$2.60B51.5%
- Operating income$819.0M16.2%
- Interest, other & tax−$22.0M0.4%
- Net income$797.0M15.7%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2025filed August 1, 2025Financial Statements
Q2 FY2025 against Q2 FY2024
| Line item | Q2 FY2025Q2 FY2024 | Change |
|---|---|---|
| Revenue | $5.06B$4.12B | +22.8% |
| Cost of Revenue | $1.64B$1.27B | +28.9% |
| Gross Profit | $3.42B$2.85B | +20.1% |
| SG&A Expenses | $1.72B$1.45B | +18.7% |
| Operating Expenses | $2.60B$2.33B | +11.8% |
| Operating Income | $819.00M$520.00M | +57.5% |
| Interest Expense | $90.00M$77.00M | +16.9% |
| Net Income | $797.00M$324.00M | +146.0% |
| EPS (Basic) | $0.54$0.22 | +145.5% |
| EPS (Diluted) | $0.53$0.22 | +140.9% |
| Shares Outstanding (Basic) | 1.48B1.47B | +0.6% |
| Shares Outstanding (Diluted) | 1.49B1.48B | +0.6% |
05—Questions
Frequently Asked Questions
What drove the significant increase in net sales?
The substantial increase in net sales was primarily driven by strong commercial execution across all business segments, particularly the Electrophysiology business unit due to the rapid adoption of the Farapulse™ Pulsed Field Ablation System. Additionally, strategic acquisitions made during the period, such as Silk Road Medical, Axonics, and Intera Oncology®, contributed to the growth, alongside organic net sales growth.
How has the company's profitability changed compared to the prior year?
Profitability has significantly improved. Net income attributable to Boston Scientific common stockholders increased to $797 million in Q2 2025 from $324 million in Q2 2024. On a diluted per share basis, this translates to $0.53 in Q2 2025 compared to $0.22 in Q2 2024. The company also reported strong adjusted net income of $1,127 million ($0.75 per diluted share) for Q2 2025, reflecting underlying operational performance.
What is the impact of the company's recent acquisitions on its financial results?
The company completed several acquisitions in the first half of 2025, including Anrei Medical, SoniVie, Intera Oncology®, and Bolt Medical. These acquisitions are expected to complement existing product portfolios and expand market reach. While not fully comparable for the entire period, they contributed positively to the reported net sales growth and are integrated into the company's operational segments.
Are there any significant charges or expenses impacting the reported results?
Yes, the company incurred several charges and credits that affected reported results. These include amortization expense, goodwill and other intangible asset impairment charges, acquisition/divestiture-related charges, restructuring and restructuring-related charges, and EU MDR implementation costs. For Q2 2025, these adjustments totaled $330 million after-tax, leading to a significant difference between reported and adjusted net income.
06—Continue